Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Diuretic

Therapeutic area intelligence for Diuretic with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 9
Catalysts: 0
Companies: 4

Companies

Annora Pharma →

Epic Pharma →

Macleods Pharmaceuticals →

Assets

Chlorthalidone →

SCPHARMACEUTICALS →

Spironolactone →

Recent signals(9)

RegulatoryAugust 5, 2026

FDA Accepts Supplement for FUROSCIX by SCPHARMACEUTICALS

The FDA has accepted a supplemental application for FUROSCIX, a formulation of furosemide.

RegulatoryAugust 3, 2026

FDA Approves Torsemide Application ANDA217239 from Micro Labs

The FDA has approved the ANDA217239 application for Torsemide submitted by Micro Labs.

RegulatoryJuly 29, 2026

FDA Accepts Supplemental NDA for FUROSCIX by SCPHARMACEUTICALS

The FDA has accepted a supplemental NDA for FUROSCIX, a formulation of furosemide.

RegulatoryJuly 22, 2026

FDA Accepts Supplement for Furosemide by Epic Pharma

The FDA has accepted a supplemental application for Furosemide submitted by Epic Pharma.

StrategyJuly 15, 2026

FDA Grants AP Status for Spironolactone ANDA219494 by Graviti Pharms

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Spironolactone submitted by Graviti Pharms.

StrategyJuly 15, 2026

FDA Grants AP Status for Spironolactone ANDA203512 by Accord Healthcare

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Spironolactone submitted by Accord Healthcare.

StrategyJuly 15, 2026

FDA Grants AP Status for Spironolactone ANDA217761 by Annora Pharma

The FDA has granted Abbreviated Approval (AP) status for Annora Pharma's ANDA217761 for spironolactone.

RegulatoryJuly 12, 2026

FDA Grants Approval for Torsemide ANDA217239 by Micro Labs

The FDA has granted approval for the ANDA217239 application for Torsemide submitted by Micro Labs.

StrategyJuly 9, 2026

FDA Grants Approval for Chlorthalidone ANDA212229 by Macleods Pharmaceuticals

The FDA has granted approval for the ANDA212229 application for Chlorthalidone submitted by Macleods Pharmaceuticals.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.